Crohn's Disease
Conditions
Interventions
Mesalazine discontinuation group:Mesalazine discontinuation
Continue mesalazine treatment group:Continue mesalazine treatment
Sponsors
The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age 18 to 80 years; 2.Patients diagnosed with Crohn's disease according to guidelines and without comorbidities such as ulcerative colitis or inflammatory bowel disease (IBD) of unclassified origin; 3.Patients with Crohn's disease requiring treatment with an anti-TNF-a agent; 4.Patients requiring treatment with an anti-TNF-a agent and concurrently receiving adequate mesalamine (1.0 g, 4 times a day, orally); 5.Patients with Crohn's disease who have achieved remission with an anti-TNF-a agent;
Exclusion criteria
Exclusion criteria: 1.Patients who have not signed the informed consent form and are unwilling to cooperate with treatment; 2.Patients with a history of intestinal surgical resection; 3.Patients with a history of anti-TNF-a use or non-response to anti-TNF-a agents; 4.Patients with other comorbidities requiring anti-TNF-a treatment; 5.Patients with severe underlying medical conditions who cannot tolerate anti-TNF-a treatment; 6.Patients who cannot tolerate mesalazine or anti-TNF-a treatment; 7.Patients with Crohn's disease-related complications such as intestinal fistulas and intestinal infections who are currently unable to use anti-TNF-a treatment;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical remission response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse reactions;Endoscopic remission response; | — |
Countries
China
Contacts
Public ContactLu Chao
The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed